356 related articles for article (PubMed ID: 22913770)
21. Real-life experience in switching to new extended half-life products at European haemophilia centres.
Peyvandi F; Garagiola I; Boscarino M; Ryan A; Hermans C; Makris M
Haemophilia; 2019 Nov; 25(6):946-952. PubMed ID: 31418967
[TBL] [Abstract][Full Text] [Related]
22. The challenge arising from the cost of haemophilia care: an audit of haemophilia treatment at Auckland Hospital.
Harper P; Brasser M; Moore L; Teague L; Pitcher L; Ockelford P
N Z Med J; 2003 Aug; 116(1180):U561. PubMed ID: 14581983
[TBL] [Abstract][Full Text] [Related]
23. Innovative coagulation factors: albumin fusion technology and recombinant single-chain factor VIII.
Schulte S
Thromb Res; 2013 Mar; 131 Suppl 2():S2-6. PubMed ID: 23537723
[TBL] [Abstract][Full Text] [Related]
24. Comparative pharmacokinetics of factor VIII and recombinant factor IX: for which coagulation factors should half-life change with age?
Björkman S
Haemophilia; 2013 Nov; 19(6):882-6. PubMed ID: 24165155
[TBL] [Abstract][Full Text] [Related]
25. Report on 4 cases with decreased recovery due to neutralizing antibodies specific for PEGylated recombinant factor VIII.
Hillarp A; Holme PA; Wåland EP; Le MS; Henriksson CE; Tjønnfjord GE; Måseide RJ
J Thromb Haemost; 2023 Oct; 21(10):2771-2775. PubMed ID: 37543216
[TBL] [Abstract][Full Text] [Related]
26. Pioneering designs for recombinant coagulation factors.
Schulte S
Thromb Res; 2011; 128 Suppl 1():S9-12. PubMed ID: 22221848
[TBL] [Abstract][Full Text] [Related]
27. [Prophylactic treatment with clotting factor to prevent joint damage in patients with severe haemophilia: costs versus benefits].
Roosendaal G; Lafeber FP
Ned Tijdschr Geneeskd; 2007 Nov; 151(47):2606-8. PubMed ID: 18161260
[TBL] [Abstract][Full Text] [Related]
28. Immune tolerance: critical issues of factor dose, purity and treatment complications.
DiMichele DM
Haemophilia; 2006 Dec; 12 Suppl 6():81-5; discussion 85-6. PubMed ID: 17123399
[TBL] [Abstract][Full Text] [Related]
29. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.
Hay CR; Brown S; Collins PW; Keeling DM; Liesner R
Br J Haematol; 2006 Jun; 133(6):591-605. PubMed ID: 16704433
[TBL] [Abstract][Full Text] [Related]
30. PROTECT VIII Kids: BAY 94-9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A.
Santagostino E; Kenet G; Fischer K; Biss T; Ahuja S; Steele M
Haemophilia; 2020 May; 26(3):e55-e65. PubMed ID: 32212300
[TBL] [Abstract][Full Text] [Related]
31. An objective method for assessing adherence to prophylaxis in adults with severe haemophilia.
Ho S; Gue D; McIntosh K; Bucevska M; Yang M; Jackson S
Haemophilia; 2014 Jan; 20(1):39-43. PubMed ID: 23919911
[TBL] [Abstract][Full Text] [Related]
32. Monitoring of modified factor VIII and IX products.
Kitchen S; Gray E; Mertens K
Haemophilia; 2014 May; 20 Suppl 4():36-42. PubMed ID: 24762273
[TBL] [Abstract][Full Text] [Related]
33. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia.
Collins PW; Fischer K; Morfini M; Blanchette VS; Björkman S;
Haemophilia; 2011 Jan; 17(1):2-10. PubMed ID: 20731726
[TBL] [Abstract][Full Text] [Related]
34. Plasma derivatives: new products and new approaches.
Sauna ZE; Pandey GS; Jain N; Mahmood I; Kimchi-Sarfaty C; Golding B
Biologicals; 2012 May; 40(3):191-5. PubMed ID: 22239993
[TBL] [Abstract][Full Text] [Related]
35. Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice.
Franchini M; Mannucci PM
Br J Clin Pharmacol; 2011 Oct; 72(4):553-62. PubMed ID: 21204915
[TBL] [Abstract][Full Text] [Related]
36. [Clinical evaluation of factors VIII and IX manufactured in Hungary, based on results of the first half year].
Nemes L; Ceglédi A; Szabó G; Varga M; Sas G
Orv Hetil; 1998 Mar; 139(13):749-52. PubMed ID: 9578703
[TBL] [Abstract][Full Text] [Related]
37. Products for the treatment of hemophilia A and B prepared by ion exchange chromatography.
Sultan Y; Boyeldieu D; Stieltjes N
Nouv Rev Fr Hematol (1978); 1994; 36 Suppl 1():S59-60. PubMed ID: 8177717
[TBL] [Abstract][Full Text] [Related]
38. Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII--an open label, exploratory, cross-over, phase I/II study.
Spira J; Plyushch O; Zozulya N; Yatuv R; Dayan I; Bleicher A; Robinson M; Baru M
Haemophilia; 2010 Nov; 16(6):910-8. PubMed ID: 20491957
[TBL] [Abstract][Full Text] [Related]
39. BAX 855, a PEGylated rFVIII product with prolonged half-life. Development, functional and structural characterisation.
Turecek PL; Bossard MJ; Graninger M; Gritsch H; Höllriegl W; Kaliwoda M; Matthiessen P; Mitterer A; Muchitsch EM; Purtscher M; Rottensteiner H; Schiviz A; Schrenk G; Siekmann J; Varadi K; Riley T; Ehrlich HJ; Schwarz HP; Scheiflinger F
Hamostaseologie; 2012; 32 Suppl 1():S29-38. PubMed ID: 22961422
[TBL] [Abstract][Full Text] [Related]
40. [New approaches to haemophilia treatment--recombinant and transgenic concentrates, gene therapy and engineered coagulation factors].
Habart D
Cas Lek Cesk; 2006; 145(2):104-11. PubMed ID: 16521398
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
